Agenus (NASDAQ:AGEN) Cut to Hold at Wall Street Zen

Agenus (NASDAQ:AGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

A number of other equities research analysts have also recently commented on AGEN. Zacks Research upgraded Agenus to a “hold” rating in a research report on Tuesday, August 12th. HC Wainwright upgraded Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, June 4th. Robert W. Baird raised their target price on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research report on Wednesday, June 4th. Finally, B. Riley restated a “buy” rating on shares of Agenus in a research report on Monday, April 21st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Agenus presently has an average rating of “Hold” and a consensus target price of $15.50.

Agenus Stock Performance

Shares of AGEN opened at $4.63 on Friday. The business’s 50-day moving average is $5.36 and its two-hundred day moving average is $3.70. The company has a market capitalization of $147.51 million, a P/E ratio of -0.65 and a beta of 1.62. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The business had revenue of $25.70 million during the quarter, compared to the consensus estimate of $49.71 million. Analysts forecast that Agenus will post -12.55 EPS for the current year.

Institutional Investors Weigh In On Agenus

Institutional investors have recently bought and sold shares of the company. Corton Capital Inc. acquired a new stake in Agenus in the 4th quarter worth about $36,000. Apollon Wealth Management LLC lifted its stake in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 5,000 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Agenus in the 2nd quarter worth approximately $50,000. Jump Financial LLC purchased a new position in Agenus in the 2nd quarter worth approximately $55,000. Finally, Acadian Asset Management LLC purchased a new position in Agenus in the 1st quarter worth approximately $58,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.